Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 31-37

  Yamaguchi, Norihiro ^a   VanderLaan, Paul A ^a   Folch, Erik ^a   Boucher, David H ^a   Canepa, Hannah M ^a   Kent, Michael S ^a   Gangadharan, Sidharta P ^a   Majid, Adnan ^a   Kocher, Olivier N ^a   Goldstein, Michael A ^a   Huberman, Mark S ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ALK; Anaplastic lymphoma kinase; EGFR; Epidermal growth factor receptor; KRAS; Lung cancer; Never smokers; Non small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; ASIAN; CAUCASIAN; EVIDENCE BASED MEDICINE; FEMALE; GENE MUTATION; GENOTYPE; GENOTYPING TECHNIQUE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NEGRO; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; SELF REPORT; SMOKING; UNITED STATES;

ALK; ANAPLASTIC LYMPHOMA KINASE; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS; LUNG CANCER; NEVER SMOKERS; NON-SMALL-CELL LUNG CANCER;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HOSPITALS, UNIVERSITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SELF REPORT; SMOKING; UNITED STATES;

EID: 84884413518     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.013     Document Type: Article

References (33)

1. Cheng L., Alexander R.E., Maclennan G.T., Cummings O.W., Montironi R., Lopez-Beltran A., et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012, 25(3):347-369.
2. Gaughan E.M., Costa D.B. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011, 3(3):113-125.
3. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
4. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
5. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29(15):2121-2127.
6. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346.
7. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
8. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
9. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6(2):201-205.
10. Nguyen K.S., Sanford R.A., Huberman M.S., Goldstein M.A., McDonald D.M., Farquhar M., et al. Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. J Oncol Pract 2012, 8(1):57-62.
11. Jackman D.M., Miller V.A., Cioffredi L.A., Yeap B.Y., Janne P.A., Riely G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15(16):5267-5273.
12. Costa D.B., Nguyen K.S., Cho B.C., Sequist L.V., Jackman D.M., Riely G.J., et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008, 14(21):7060-7067.
13. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
14. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
15. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
16. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98(12):1817-1824.
17. Dogan S., Shen R., Ang D.C., Johnson M.L., D'Angelo S.P., Paik P.K., et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012, 18(22):6169-6177.
18. Li C., Fang R., Sun Y., Han X., Li F., Gao B., et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 2011, 6(11):e28204.
19. Janne P.A., Wang X., Socinski M.A., Crawford J., Stinchcombe T.E., Gu L., et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012, 30(17):2063-2069.
20. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
21. Varghese A.M., Sima C.S., Chaft J.E., Johnson M.L., Riely G.J., Ladanyi M., et al. Lungs don't forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J Thorac Oncol 2013, 8(1):123-125.
22. Matsuo K., Ito H., Yatabe Y., Hiraki A., Hirose K., Wakai K., et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2007, 98(1):96-101.
23. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
24. Ou S.H., Bartlett C.H., Mino-Kenudson M., Cui J., Iafrate A.J. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012, 17(11):1351-1375.
25. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. J Clin Oncol 2013, 31(8):1105-1111.
26. Cardarella S., Ortiz T.M., Joshi V.A., Butaney M., Jackman D.M., Kwiatkowski D.J., et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 2012, 7(12):1767-1774.
27. Ettinger D.S., Akerley W., Borghaei H., Chang A.C., Cheney R.T., Chirieac L.R., et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2012, 10(10):1236-1271.
28. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer - early successes and future challenges. Nat Rev Clin Oncol 2012, 9(5):268-277.
29. Chen Z., Cheng K., Walton Z., Wang Y., Ebi H., Shimamura T., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483(7391):613-617.
30. Janne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14(1):38-47.
31. Oxnard G.R., Binder A., Janne P.A. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31(8):1097-1104.
32. Yasuda H., Figueiredo-Pontes L.L., Kobayashi S., Costa D.B. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012, 7(7):1086-1090.
33. Wagle N., Berger M.F., Davis M.J., Blumenstiel B., Defelice M., Pochanard P., et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012, 2(1):82-93.